 NEW YORK, Aug. 20, 2021 GLOBE NEWSWIRE -- Brooklyn ImmunoTherapeutics, Inc. NYSE American: BTX Brooklyn, a biopharmaceutical company focused on exploring the role that cytokine and gene editingcell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D. on August 19, 2021. 